Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million before expenses [1][2]. Group 1: Offering Details - The public offering consists entirely of shares sold by the Company, with underwriters granted a 30-day option to purchase an additional 5,217,391 shares [2]. - The Offering is expected to close on January 22, 2026, pending customary closing conditions [1]. - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on January 8, 2026 [6]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, contingent on the completion of the public offering [3]. - The private placement will require a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the Offering and the Private Placement will support the growth and clinical strategy of the Company, including the DurAVR Transcatheter Heart Valve global pivotal trial [4]. - Funds will also be allocated to expand manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining proceeds for working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is focused on developing innovative medical devices for heart function restoration, with a significant presence in both Australia and the USA [10]. - The lead product, DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [11].

Core Viewpoint - Anteris Technologies Global Corp. is initiating a public offering of $200 million in common stock, with an additional $30 million option for underwriters, alongside a private placement of up to $90 million to Medtronic plc, aimed at supporting growth and clinical strategy execution [1][2][3]. Group 1: Offering Details - The company is offering $200 million of its common stock through a proposed underwritten public offering, with a 30-day option for underwriters to purchase an additional $30 million [1]. - Anteris has agreed to sell up to $90 million of common stock to Medtronic in a private placement, contingent on the completion of the public offering [2]. - The shares in the public offering are being offered under a shelf registration statement filed with the SEC, effective January 8, 2026 [5]. Group 2: Use of Proceeds - The net proceeds from the offering and private placement will be used to support the next stage of growth, including the PARADIGM Trial for the DurAVR Transcatheter Heart Valve and expansion of manufacturing capabilities [3]. - A portion of the proceeds will also fund ongoing research and development for v2vmedtech, inc., with the remainder allocated to working capital and general corporate purposes [3]. Group 3: Company Overview - Anteris Technologies is a global structural heart company focused on developing medical devices to restore heart function, with a significant presence in both Australia and the USA [9]. - The company's lead product, the DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [10].